Patients with multiple myeloma were randomly assigned at a one-to-one ratio to receive either aprepitant ( @ mg orally on day @ and @ mg orally on days @ to @ ) , granisetron ( @ mg orally on days @ to @ ) , and dexamethasone ( @ mg orally on day @ and @ mg orally on days @ to @ ) or matching placebo , granisetron ( @ mg orally on days @ to @ ) , and dexamethasone ( @ mg orally on day @ and @ mg orally on days @ to @ ) .